{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T02:26:33Z","timestamp":1770431193046,"version":"3.49.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,5,1]]},"DOI":"10.1093\/alcalc\/agh151","type":"journal-article","created":{"date-parts":[[2005,3,30]],"date-time":"2005-03-30T01:12:55Z","timestamp":1112145175000},"page":"227-233","source":"Crossref","is-referenced-by-count":65,"title":["CLINICAL PREDICTORS OF RESPONSE TO NALTREXONE IN ALCOHOLIC PATIENTS: WHO BENEFITS MOST FROM TREATMENT WITH NALTREXONE?"],"prefix":"10.1093","volume":"40","author":[{"given":"G.","family":"RUBIO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"PONCE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"RODRIGUEZ-JIM\u00c9NEZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"JIM\u00c9NEZ-ARRIERO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"HOENICKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"PALOMO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,3,29]]},"reference":[{"key":"key\n\t\t\t\t20171010165419_B1","unstructured":"American Psychiatric Association (1994) Diagnosis and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association Press, Washington DC."},{"key":"key\n\t\t\t\t20171010165419_B2","doi-asserted-by":"crossref","unstructured":"Anton, R. F., Moak, D. H., Waid, L. R. et al. (1999) Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. American Journal of Psychiatry156, 1758\u20131764.","DOI":"10.1176\/ajp.156.11.1758"},{"key":"key\n\t\t\t\t20171010165419_B3","doi-asserted-by":"crossref","unstructured":"Babor, T. F., Hofmann, M., DelBoca, F. K. et al. (1992) Types of alcoholics: I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Archives of General Psychiatry49, 599\u2013608.","DOI":"10.1001\/archpsyc.1992.01820080007002"},{"key":"key\n\t\t\t\t20171010165419_B4","doi-asserted-by":"crossref","unstructured":"Balldin, J., Berglund, M., Borg, S. et al. (2003). A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcoholism: Clinical and Experimental Research27, 1142\u20131149.","DOI":"10.1097\/01.ALC.0000075548.83053.A9"},{"key":"key\n\t\t\t\t20171010165419_B5","doi-asserted-by":"crossref","unstructured":"Benjamin, D., Grant, E. R. and Phorecky, L. (1993) Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Research621, 137\u2013140.","DOI":"10.1016\/0006-8993(93)90309-B"},{"key":"key\n\t\t\t\t20171010165419_B6","doi-asserted-by":"crossref","unstructured":"Blum, K., Noble, E. P., Sheridan, P. J. et al. (1990) Allelic association of human dopamine D2 receptor gene in alcoholism. The Journal of American Medical Association263, 2055\u20132060.","DOI":"10.1001\/jama.1990.03440150063027"},{"key":"key\n\t\t\t\t20171010165419_B7","unstructured":"Bueno, J. A., Humbert, M., Sabanes, F. et al. (1989) Sistema RDC. Criterios diagn\u00f3sticos de Investigaci\u00f3n (Research Diagnostic Criteria), Instituto de Medicina Psicol\u00f3gica de Barcelona. Editores M\u00e9dicos SA, Madrid."},{"key":"key\n\t\t\t\t20171010165419_B8","doi-asserted-by":"crossref","unstructured":"Chick, J., Anton, R., Checinski, K. et al. (2000) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol and Alcoholism35, 587\u2013593.","DOI":"10.1093\/alcalc\/35.6.587"},{"key":"key\n\t\t\t\t20171010165419_B9","doi-asserted-by":"crossref","unstructured":"Cloninger, R., Sigvardson, S., Gilligan, S. et al. (1988) Genetic heterogeneity and the Classification of Alcoholism. Advances on Alcoholism and Substance Abuse7, 3\u201317.","DOI":"10.1300\/J251v07n03_02"},{"key":"key\n\t\t\t\t20171010165419_B10","doi-asserted-by":"crossref","unstructured":"Di Chiara, G. and Imperato, A. (1988) Drug abused by humans preferentially increase synaptic dopamine concentration in the mesolimbic system of freely moving rats. Proceeding of the National Academy of Sciences of the United States of America85, 5274.","DOI":"10.1073\/pnas.85.14.5274"},{"key":"key\n\t\t\t\t20171010165419_B11","doi-asserted-by":"crossref","unstructured":"Di Chiara, G., Acquas, E. and Tanda, G. (1996) Ethanol as a neurochemical surrogate of conventional reinforcers: the dopamine-opioid link. Alcohol13, 13\u201317.","DOI":"10.1016\/0741-8329(95)02034-9"},{"key":"key\n\t\t\t\t20171010165419_B12","unstructured":"Firsts, M. B., Spitzer, R. L. and Williams, J. B. (1995) Structured Clinical Interview for DSM-IV Axis I Disorders Patient Edition (SCID-IP, Version 2.0). New York."},{"key":"key\n\t\t\t\t20171010165419_B13","doi-asserted-by":"crossref","unstructured":"Gastpar, M., Bonnet, U., Boning, J. et al. (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. Journal of Clinical Psychopharmacology22, 592\u2013598.","DOI":"10.1097\/00004714-200212000-00009"},{"key":"key\n\t\t\t\t20171010165419_B14","doi-asserted-by":"crossref","unstructured":"Gianoulakis, C., Beliveau, D., Agelogianni, P. et al. (1989) Different pituitary beta-endorphin and adrenal cortisol response to ethanol in individuals with high and low risk for future development of alcoholism. Life Sciences45, 1097\u20131109.","DOI":"10.1016\/0024-3205(89)90167-7"},{"key":"key\n\t\t\t\t20171010165419_B15","doi-asserted-by":"crossref","unstructured":"Gianoulakis, C., De Waele, J. P. and Kiianmaa, K. (1992) Differences in the brain and pituitary beta-endorphin system between the alcohol-preferring AA and alcohol-avoiding ANA rats. Alcoholism: Clinical and Experimental Research16, 453\u2013459.","DOI":"10.1111\/j.1530-0277.1992.tb01399.x"},{"key":"key\n\t\t\t\t20171010165419_B16","doi-asserted-by":"crossref","unstructured":"Guardia, J., Caso, C., Arias, F. et al. (2002) A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcoholism: Clinical and Experimental Research26, 1381\u20131387.","DOI":"10.1111\/j.1530-0277.2002.tb02682.x"},{"key":"key\n\t\t\t\t20171010165419_B17","unstructured":"Goodwin, D. W. (1985) Genetic determinants of alcoholism. In Genetic Determinants of Alcoholism, Mendelson, J. H. and Mello, N. K. eds, pp. 55\u201370. McGraw-Hill Book Company, New York."},{"key":"key\n\t\t\t\t20171010165419_B18","unstructured":"Jimenez-Arriero, M. A., Ponce, G., Huidobro, A. et al. (1998) Clinical evidence of naltrexone efficacy in the treatment of alcohol dependence. In Interactive Monoaminergic Basis of Brain Disorders, Palomo, T., Beninger, R. J. and Archer, T. eds, pp. 275\u2013290. Edit. S\u00edntesis, Madrid."},{"key":"key\n\t\t\t\t20171010165419_B19","doi-asserted-by":"crossref","unstructured":"King, A. C., Volpicelli, J. R., Frazer, A. et al. (1997) Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl)129, 15\u201322.","DOI":"10.1007\/s002130050156"},{"key":"key\n\t\t\t\t20171010165419_B20","doi-asserted-by":"crossref","unstructured":"Koob, G. F. and Bloom, F. E. (1988) Cellular and molecular mechanisms of drug dependence. Science242, 715\u2013723.","DOI":"10.1126\/science.2903550"},{"key":"key\n\t\t\t\t20171010165419_B21","doi-asserted-by":"crossref","unstructured":"Kranzler, H. R., Armeli, S., Tennen, H. et al. (2003) Targeted naltrexone for early problem drinkers. Journal of Clinical Psychopharmacology23, 294\u2013304.","DOI":"10.1097\/01.jcp.0000084030.22282.6d"},{"key":"key\n\t\t\t\t20171010165419_B22","doi-asserted-by":"crossref","unstructured":"Krystal, J. H., Cramer, J. A., Krol, W. F. et al. (2001) Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine345, 1734\u20131739.","DOI":"10.1056\/NEJMoa011127"},{"key":"key\n\t\t\t\t20171010165419_B23","doi-asserted-by":"crossref","unstructured":"Latt, N. C., Jurd, S., Houseman, J. et al. (2002) Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Medical Journal of Australia176, 530\u2013534.","DOI":"10.5694\/j.1326-5377.2002.tb04550.x"},{"key":"key\n\t\t\t\t20171010165419_B24","doi-asserted-by":"crossref","unstructured":"McLellan, A. T., Luborsky, L., Woody, G. E. et al. (1980) An improved diagnostic evaluation instrument for substance abuse patients: the Addiction Severity Index. Journal of Nervous and Mental Disease168, 26\u201333.","DOI":"10.1097\/00005053-198001000-00006"},{"key":"key\n\t\t\t\t20171010165419_B25","doi-asserted-by":"crossref","unstructured":"Miller, W. R. (1996) Form 90: A Structured Assessment Interview for Drinking and Related Behaviors Test Manual: NIAAA Project Match Monograph Series, vol. 5, Mattson, M. E. and Marshall, L. A. eds, pp. 14\u201322, National Institute on Alcoholism and Alcohol Abuse, Rockville, MD.","DOI":"10.1037\/e563242012-001"},{"key":"key\n\t\t\t\t20171010165419_B26","doi-asserted-by":"crossref","unstructured":"Monterosso, J. R., Flannery, B. A., Pettinati, H. M. et al. (2001) Predicting treatment response to naltrexone: the influence of craving and family history. American Journal of Addictions10, 258\u2013268.","DOI":"10.1080\/105504901750532148"},{"key":"key\n\t\t\t\t20171010165419_B27","doi-asserted-by":"crossref","unstructured":"Morris, P. L., Hopwood, M., Whelan, G. et al. (2001) Naltrexone for alcohol dependence: a randomized controlled trial. Addiction96, 1565\u20131573.","DOI":"10.1046\/j.1360-0443.2001.961115654.x"},{"key":"key\n\t\t\t\t20171010165419_B28","doi-asserted-by":"crossref","unstructured":"Na, C. and Lee, Y. S. (2002) Alcohol urge and plasma beta-endorphin change after alcohol challenge with naltrexone pretreatment in social drinkers. Progress in Neuro-Psychopharmacology & Biological Psychiatry26, 663\u2013670.","DOI":"10.1016\/S0278-5846(01)00315-3"},{"key":"key\n\t\t\t\t20171010165419_B29","doi-asserted-by":"crossref","unstructured":"Noble, E. P. (2000) Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review. European Psychiatry15, 79\u201389.","DOI":"10.1016\/S0924-9338(00)00208-X"},{"key":"key\n\t\t\t\t20171010165419_B30","doi-asserted-by":"crossref","unstructured":"O'Malley, S. S., Jaffe, A. J., Chang, G. et al. (1992) Naltrexone and coping skills therapy for alcohol dependence. Archives of General Psychiatry49, 881\u2013887.","DOI":"10.1001\/archpsyc.1992.01820110045007"},{"key":"key\n\t\t\t\t20171010165419_B31","doi-asserted-by":"crossref","unstructured":"O'Malley, S. S., Jaffe, A. J., Rode, S. et al. (1996) Experience of a \u2018slip\u2019 among alcoholics treated with naltrexone or placebo. American Journal of Psychiatry153, 281\u2013283.","DOI":"10.1176\/ajp.153.2.281"},{"key":"key\n\t\t\t\t20171010165419_B32","doi-asserted-by":"crossref","unstructured":"Oslin, D. W., Berrettini, W., Kranzler, H. R. et al. (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology28, 1546\u20131552.","DOI":"10.1038\/sj.npp.1300219"},{"key":"key\n\t\t\t\t20171010165419_B33","unstructured":"Paille, F. M., Guelfi, J. D., Perkins, A. C. et al. (1995) Randomised multicentre trial of acamprosate in a maintenance programme of abstinence after alcohol detoxification. Alcohol and Alcoholism30, 239\u2013247."},{"key":"key\n\t\t\t\t20171010165419_B34","doi-asserted-by":"crossref","unstructured":"Rubio, G., Jimenez-Arriero, M. A., Ponce, G. et al. (2001) Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol and Alcoholism36, 419\u2013425.","DOI":"10.1093\/alcalc\/36.5.419"},{"key":"key\n\t\t\t\t20171010165419_B35","doi-asserted-by":"crossref","unstructured":"Rubio, G., Ponce, G. and Manzanares, J. (2002) Naltrexone for alcohol dependence. New England Journal of Medicine346, 1329\u20131331.","DOI":"10.1056\/NEJM200204253461716"},{"key":"key\n\t\t\t\t20171010165419_B36","unstructured":"Rubio, G., Urosa, B. and Santo-Domingo, J. (1998). Validaci\u00f3n de la escala de la intensidad de la dependencia alcoh\u00f3lica (EIDA). Psiquiatr\u00eda Biol\u00f3gica (Suppl. 1), 44\u201347."},{"key":"key\n\t\t\t\t20171010165419_B37","doi-asserted-by":"crossref","unstructured":"Sass, H., Soyka, M., Mann, K. et al. (1996) Relapse prevention by acamprosate: results from a placebo controlled study on alcohol dependence. Archives of General Psychiatry53, 673\u2013680.","DOI":"10.1001\/archpsyc.1996.01830080023006"},{"key":"key\n\t\t\t\t20171010165419_B38","doi-asserted-by":"crossref","unstructured":"Stockwell, T. R., Hodgson, R. J., Edwards, G. et al. (1979) The development of a questionnaire to measure severity of alcohol dependence. British Journal of Addiction74, 79\u201387.","DOI":"10.1111\/j.1360-0443.1979.tb02415.x"},{"key":"key\n\t\t\t\t20171010165419_B39","doi-asserted-by":"crossref","unstructured":"Volpicelli, J. R., Davis, M. A. and Olgin, J. E. (1986) Naltrexone blocks the post-shock increase of ethanol consumption. Life Sciences38, 841\u2013847.","DOI":"10.1016\/0024-3205(86)90601-6"},{"key":"key\n\t\t\t\t20171010165419_B40","doi-asserted-by":"crossref","unstructured":"Volpicelli, J. R., Alterman, A. I., Hayashida, M. et al. (1992) Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry49, 876\u2013880.","DOI":"10.1001\/archpsyc.1992.01820110040006"},{"key":"key\n\t\t\t\t20171010165419_B41","doi-asserted-by":"crossref","unstructured":"Volpicelli, J. R., Watson, N. T., King, A. C. et al. (1995) Effect of naltrexone on alcohol 'high' in alcoholics. American Journal of Psychiatry152, 613\u2013615.","DOI":"10.1176\/ajp.152.4.613"},{"key":"key\n\t\t\t\t20171010165419_B42","unstructured":"Volpicelli, J. R., Clay, K. L., Watson, N. T. et al. (1995) Naltrexone in the treatment of alcoholism: predicting response to naltrexone. Journal of Clinical Psychiatry56, 39\u201344."}],"container-title":["Alcohol and Alcoholism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/alcalc\/article-pdf\/40\/3\/227\/6657044\/agh151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T11:46:22Z","timestamp":1706096782000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/alcalc\/article\/40\/3\/227\/154952\/CLINICAL-PREDICTORS-OF-RESPONSE-TO-NALTREXONE-IN"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,29]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2005,3,29]]},"published-print":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/alcalc\/agh151","relation":{},"ISSN":["1464-3502","0735-0414"],"issn-type":[{"value":"1464-3502","type":"electronic"},{"value":"0735-0414","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,5]]},"published":{"date-parts":[[2005,3,29]]}}}